

# Manuel Monreal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2630966/publications.pdf>

Version: 2024-02-01

272  
papers

18,966  
citations

26630

56  
h-index

12946

131  
g-index

286  
all docs

286  
docs citations

286  
times ranked

16618  
citing authors

#	ARTICLE	IF	CITATIONS
1	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2014, 35, 3033-3080.	2.2	2,591
2	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973.	2.8	2,392
3	Simplification of the Pulmonary Embolism Severity Index for Prognostication in Patients With Acute Symptomatic Pulmonary Embolism. <i>Archives of Internal Medicine</i> , 2010, 170, 1383.	3.8	959
4	Clinical Predictors for Fatal Pulmonary Embolism in 15 520 Patients With Venous Thromboembolism. <i>Circulation</i> , 2008, 117, 1711-1716.	1.6	602
5	Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1620.	7.4	515
6	International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 56-70.	3.8	469
7	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Lancet Oncology</i> , The, 2019, 20, e566-e581.	10.7	458
8	Venous Thromboembolism Prophylaxis in Acutely Ill Hospitalized Medical Patients. <i>Chest</i> , 2007, 132, 936-945.	0.8	446
9	Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. <i>Thrombosis and Haemostasis</i> , 2008, 100, 26-31.	3.4	417
10	Predictive and Associative Models to Identify Hospitalized Medical Patients at Risk for VTE. <i>Chest</i> , 2011, 140, 706-714.	0.8	401
11	Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019. <i>Chest</i> , 2021, 159, 1182-1196.	0.8	361
12	Factors at Admission Associated With Bleeding Risk in Medical Patients. <i>Chest</i> , 2011, 139, 69-79.	0.8	347
13	Clinical Outcome of Patients With Upper-Extremity Deep Vein Thrombosis. <i>Chest</i> , 2008, 133, 143-148.	0.8	289
14	Trends in the Management and Outcomes of Acute Pulmonary Embolism. <i>Journal of the American College of Cardiology</i> , 2016, 67, 162-170.	2.8	271
15	International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 71-80.	3.8	252
16	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024.	3.4	206
17	Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1950-1956.	3.8	193
18	Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1028-1035.	3.8	193

#	ARTICLE	IF	CITATIONS
19	Troponin-Based Risk Stratification of Patients With Acute Nonmassive Pulmonary Embolism. <i>Chest</i> , 2009, 136, 974-982.	0.8	179
20	Survival Effects of Inferior Vena Cava Filter in Patients With Acute Symptomatic Venous Thromboembolism and a Significant Bleeding Risk. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1675-1683.	2.8	167
21	Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1216-1222.	3.8	164
22	Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. <i>Thrombosis Research</i> , 2013, 131, 24-30.	1.7	162
23	Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2008, 100, 435-439.	3.4	161
24	Rationale, Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE). <i>Thrombosis and Haemostasis</i> , 2018, 118, 214-224.	3.4	160
25	The outcome after treatment of venous thromboembolism is different in surgical and acutely ill medical patients. Findings from the RIETE registry. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 1892-1898.	3.8	157
26	Prognostic Significance of Deep Vein Thrombosis in Patients Presenting with Acute Symptomatic Pulmonary Embolism. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 983-991.	5.6	154
27	Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1903-1921.	2.8	150
28	2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. <i>Lancet Oncology</i> , The, 2022, 23, e334-e347.	10.7	138
29	Inferior Vena Cava Filters to Prevent Pulmonary Embolism. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1587-1597.	2.8	134
30	Venous Thromboembolism in Patients with Renal Insufficiency: Findings from the RIETE Registry. <i>American Journal of Medicine</i> , 2006, 119, 1073-1079.	1.5	130
31	Combinations of prognostic tools for identification of high-risk normotensive patients with acute symptomatic pulmonary embolism. <i>Thorax</i> , 2011, 66, 75-81.	5.6	115
32	Deep venous thrombosis and the risk of pulmonary embolism. A systematic study.. <i>Chest</i> , 1992, 102, 677.	0.8	115
33	Platelet Count and Survival in Patients with Colorectal Cancer – a Preliminary Study. <i>Thrombosis and Haemostasis</i> , 1998, 79, 916-918.	3.4	112
34	Venous thromboembolism during pregnancy or postpartum: Findings from the RIETE Registry. <i>Thrombosis and Haemostasis</i> , 2007, 97, 186-190.	3.4	111
35	Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 105-113.	3.8	105
36	Dynamics of case-fatality rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2013, 110, 834-843.	3.4	94

#	ARTICLE	IF	CITATIONS
37	Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE). <i>Haematologica</i> , 2006, 91, 1046-51.	3.5	93
38	Trends in hospital admissions for pulmonary embolism in Spain from 2002 to 2011. <i>European Respiratory Journal</i> , 2014, 44, 942-950.	6.7	88
39	Clinical presentation and time-course of postoperative venous thromboembolism: Results from the RIETE Registry. <i>Thrombosis and Haemostasis</i> , 2008, 99, 546-551.	3.4	84
40	The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site. <i>American Journal of Medicine</i> , 2017, 130, 337-347.	1.5	83
41	Clinical presentation and outcome of venous thromboembolism in COPD. <i>European Respiratory Journal</i> , 2012, 39, 862-868.	6.7	80
42	The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE). <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 856-862.	3.8	79
43	Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry. <i>Thrombosis Research</i> , 2009, 124, 174-177.	1.7	78
44	The management of acute venous thromboembolism in clinical practice. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1326-1337.	3.4	74
45	Clinical Syndromes and Clinical Outcome in Patients With Pulmonary Embolism. <i>Chest</i> , 2006, 130, 1817-1822.	0.8	72
46	Pulmonary Embolism Hospitalization, Readmission, and Mortality Rates in US Older Adults, 1999-2015. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 574.	7.4	69
47	Pulmonary Embolism in Patients with Chronic Obstructive Pulmonary Disease or Congestive Heart Failure. <i>American Journal of Medicine</i> , 2006, 119, 851-858.	1.5	68
48	A Prospective Double-blind Trial of a Low Molecular Weight Heparin Once Daily Compared with Conventional Low-dose Heparin Three Times Daily to Prevent Pulmonary Embolism and Venous Thrombosis in Patients with Hip Fracture. <i>Journal of Trauma</i> , 1989, 29, 873-875.	2.3	67
49	Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia. <i>European Journal of Clinical Pharmacology</i> , 1989, 37, 415-418.	1.9	66
50	Clinical outcome of patients with venous thromboembolism and renal insufficiency. <i>Thrombosis and Haemostasis</i> , 2007, 98, 771-776.	3.4	65
51	Prognostic significance of tricuspid annular displacement in normotensive patients with acute symptomatic pulmonary embolism. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1020-1027.	3.8	64
52	Clinical outcome in patients with venous thromboembolism and hidden cancer: findings from the RIETE Registry. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 251-255.	3.8	62
53	Thrombolytic therapy and outcome of patients with an acute symptomatic pulmonary embolism. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 751-759.	3.8	62
54	Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies. <i>Thrombosis Research</i> , 2020, 196, 382-394.	1.7	62

#	ARTICLE	IF	CITATIONS
55	Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens. <i>Thrombosis and Haemostasis</i> , 2017, 117, 382-389.	3.4	59
56	A Clinical Prognostic Model for the Identification of Low-Risk Patients With Acute Symptomatic Pulmonary Embolism and Active Cancer. <i>Chest</i> , 2013, 143, 138-145.	0.8	58
57	Right heart thrombi in pulmonary embolism. <i>European Respiratory Journal</i> , 2016, 48, 1377-1385.	6.7	58
58	Dâ€dimer levels and 15â€day outcome in acute pulmonary embolism. Findings from the RIETE Registry. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1795-1801.	3.8	57
59	Silent pulmonary embolism in patients with proximal deep vein thrombosis in the lower limbs. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 564-571.	3.8	53
60	Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2015, 20, 490-500.	2.0	53
61	Management of Patients with Acute Venous Thromboembolism: Findings from the RIETE Registry. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2003, 33, 330-334.	0.3	52
62	Venous thromboembolism in Spain. Comparison between an administrative database and the RIETE registry. <i>European Journal of Internal Medicine</i> , 2008, 19, 443-446.	2.2	51
63	Effects of age on the risk of dying from pulmonary embolism or bleeding during treatment of deep vein thrombosis. <i>Journal of Vascular Surgery</i> , 2011, 54, 26S-32S.	1.1	51
64	Development of a Risk Prediction Score for Occult Cancer in Patients With VTE. <i>Chest</i> , 2017, 151, 564-571.	0.8	51
65	Low-molecular-weight or Unfractionated Heparin in Venous Thromboembolism: The Influence of Renal Function. <i>American Journal of Medicine</i> , 2013, 126, 425-434.e1.	1.5	49
66	Clinical outcome of patients with venous thromboembolism and recent major bleeding: findings from a prospective registry (RIETE). <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 703-709.	3.8	48
67	Sex Differences in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism. <i>Medicine (United States)</i> , 2014, 93, 309-317.	1.0	48
68	Venous Thromboembolism in Women Undergoing Assisted Reproductive Technologies: Data from the RIETE Registry. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1962-1968.	3.4	48
69	Bleeding complications associated with anticoagulant therapy in patients with cancer. <i>Thrombosis Research</i> , 2010, 125, S58-S61.	1.7	47
70	Venous thromboembolism in women using hormonal contraceptives. <i>Thrombosis and Haemostasis</i> , 2009, 101, 478-482.	3.4	46
71	Acute venous thromboembolism in patients with recent major bleeding. The influence of the site of bleeding and the time elapsed on outcome. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2367-2372.	3.8	45
72	Venous thromboembolism in radiation therapy cancer patients: Findings from the RIETE registry. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 83-89.	4.4	45

#	ARTICLE	IF	CITATIONS
73	Treatment of Right Heart Thrombi Associated with Acute Pulmonary Embolism. American Journal of Medicine, 2017, 130, 588-595.	1.5	45
74	Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism. Thrombosis Research, 2013, 132, 175-179.	1.7	44
75	Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19. Journal of the American College of Cardiology, 2021, 78, 408-411.	2.8	44
76	Predicting adverse outcome in outpatients with acute deep vein thrombosis. Findings from the RIETE Registry. Journal of Vascular Surgery, 2006, 44, 789-793.	1.1	43
77	Smoking cessation and outcome in stable outpatients with coronary, cerebrovascular, or peripheral artery disease. European Journal of Preventive Cardiology, 2013, 20, 486-495.	1.8	43
78	Fatal Events in Cancer Patients Receiving Anticoagulant Therapy for Venous Thromboembolism. Medicine (United States), 2015, 94, e1235.	1.0	43
79	Bleeding risk in hospitalized patients with COVID-19 receiving intermediate- or therapeutic doses of thromboprophylaxis. Journal of Thrombosis and Haemostasis, 2021, 19, 1981-1989.	3.8	42
80	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19. Journal of the American College of Cardiology, 2021, 78, 1635-1654.	2.8	42
81	Arterial Ischemic Events Are a Major Complication in Cancer Patients with Venous Thromboembolism. American Journal of Medicine, 2018, 131, 1095-1103.	1.5	41
82	Epidemiology, patterns of care and mortality for patients with hemodynamically unstable acute symptomatic pulmonary embolism. International Journal of Cardiology, 2018, 269, 327-333.	1.7	41
83	Hospital volume and outcomes for acute pulmonary embolism: multinational population based cohort study. BMJ: British Medical Journal, 2019, 366, 14416.	2.3	41
84	The management of acute venous thromboembolism in clinical practice – study rationale and protocol of the European PREFER in VTE Registry. Thrombosis Journal, 2015, 13, 41.	2.1	40
85	Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function. European Journal of Preventive Cardiology, 2022, 29, 1248-1263.	1.8	40
86	Major bleeding as a predictor of mortality in patients with venous thromboembolism: findings from the RIETE Registry. Journal of Thrombosis and Haemostasis, 2010, 8, 2575-2577.	3.8	38
87	Long-Term Anticoagulant Therapy of Patients with Venous Thromboembolism. What Are the Practices?. PLoS ONE, 2015, 10, e0128741.	2.5	38
88	Meta-Analysis of Prevalence and Short-Term Prognosis of Hemodynamically Unstable Patients With Symptomatic Acute Pulmonary Embolism. American Journal of Cardiology, 2019, 123, 684-689.	1.6	36
89	Body mass index and outcome in patients with coronary, cerebrovascular, or peripheral artery disease: findings from the FRENA registry. European Journal of Cardiovascular Prevention and Rehabilitation, 2009, 16, 457-463.	2.8	35
90	Home versus in-hospital treatment of outpatients with acute deep venous thrombosis of the lower limbs. Journal of Vascular Surgery, 2014, 59, 1362-1367.e1.	1.1	35

#	ARTICLE	IF	CITATIONS
91	Outcomes during anticoagulation in patients with symptomatic vs. incidental splanchnic vein thrombosis. <i>Thrombosis Research</i> , 2018, 164, 69-74.	1.7	35
92	Comparison of four scores to predict major bleeding in patients receiving anticoagulation for venous thromboembolism: findings from the RIETE registry. <i>Internal and Emergency Medicine</i> , 2014, 9, 847-852.	2.0	34
93	Presenting Characteristics, Treatment Patterns, and Outcomes among Patients with Venous Thromboembolism during Hospitalization for COVID-19. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 351-361.	2.7	34
94	Lipoprotein (a) levels and outcomes in stable outpatients with symptomatic artery disease. <i>Atherosclerosis</i> , 2018, 276, 10-14.	0.8	33
95	Management appropriateness and outcomes of patients with acute pulmonary embolism. <i>European Respiratory Journal</i> , 2018, 51, 1800445.	6.7	33
96	Clinical outcome of stable outpatients with coronary, cerebrovascular or peripheral artery disease, and atrial fibrillation. <i>Thrombosis Research</i> , 2012, 130, 390-395.	1.7	32
97	Impact of sex, age, and risk factors for venous thromboembolism on the initial presentation of first isolated symptomatic acute deep vein thrombosis. <i>Thrombosis Research</i> , 2019, 173, 166-171.	1.7	32
98	Clinical characteristics and outcome of inpatients versus outpatients with venous thromboembolism. <i>European Journal of Internal Medicine</i> , 2010, 21, 377-382.	2.2	31
99	Outcomes Associated With Inferior Vena Cava Filters Among Patients With Thromboembolic Recurrence During Anticoagulant Therapy. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2440-2448.	2.9	31
100	Influence of recent immobilization and recent surgery on mortality in patients with pulmonary embolism. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1752-1760.	3.8	30
101	Venous thromboembolism in nonagenarians. <i>Thrombosis and Haemostasis</i> , 2009, 101, 1112-1118.	3.4	30
102	Pulmonary embolism in Europe - Burden of illness in relationship to healthcare resource utilization and return to work. <i>Thrombosis Research</i> , 2018, 170, 181-191.	1.7	29
103	VTE Registry: What Can Be Learned from RIETE?. <i>Rambam Maimonides Medical Journal</i> , 2014, 5, e0037.	1.0	27
104	Identification of Low-Risk Patients with Acute Symptomatic Pulmonary Embolism for Outpatient Therapy. <i>Annals of the American Thoracic Society</i> , 2015, 12, 150626095350002.	3.2	27
105	Frequency and prognostic impact of acute kidney injury in patients with acute pulmonary embolism. Data from the RIETE registry. <i>International Journal of Cardiology</i> , 2019, 291, 121-126.	1.7	27
106	Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017, 1, 172-179.	2.3	26
107	Recurrent pulmonary embolism in patients treated because of acute venous thromboembolism: A prospective study. <i>European Journal of Vascular Surgery</i> , 1994, 8, 584-589.	0.9	25
108	Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study. <i>Thrombosis and Haemostasis</i> , 2022, 122, 646-656.	3.4	25

#	ARTICLE	IF	CITATIONS
109	Fever and deep venous thrombosis. Findings from the RIETE registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 288-292.	2.1	24
110	Trend and seasonality in hospitalizations for pulmonary embolism: a time-series analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 23-30.	3.8	24
111	DVT Management and Outcome Trends, 2001 to 2014. <i>Chest</i> , 2016, 150, 374-383.	0.8	23
112	Real-life Use of Anticoagulants in Venous Thromboembolism With a Focus on Patients With Exclusion Criteria for Direct Oral Anticoagulants. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 684-691.	4.7	23
113	Platelet Count, Antiplatelet Therapy and Pulmonary Embolism-A Prospective Study in Patients with Hip Surgery. <i>Thrombosis and Haemostasis</i> , 1995, 73, 380-385.	3.4	23
114	Venous thromboembolism in women taking hormonal contraceptives. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 211-215.	1.5	22
115	Glucose control and outcome in patients with stable diabetes and previous coronary, cerebrovascular or peripheral artery disease. Findings from the FRENA Registry. <i>Diabetic Medicine</i> , 2011, 28, 73-80.	2.3	21
116	Long-term therapy with low-molecular-weight heparin in cancer patients with venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2012, 107, 37-43.	3.4	21
117	Outcome during and after anticoagulant therapy in cancer patients with incidentally found pulmonary embolism. <i>European Respiratory Journal</i> , 2016, 48, 1360-1368.	6.7	21
118	Clinical Prognosis of Nonmassive Central and Noncentral Pulmonary Embolism. <i>Chest</i> , 2017, 151, 829-837.	0.8	21
119	Predictors of Post-Thrombotic Ulcer after Acute DVT: The RIETE Registry. <i>Thrombosis and Haemostasis</i> , 2018, 118, 320-328.	3.4	21
120	Alcohol consumption and outcome in stable outpatients with peripheral artery disease. <i>Journal of Vascular Surgery</i> , 2011, 54, 1081-1087.	1.1	20
121	Outcomes in Neurosurgical Patients Who Develop Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2014, 20, 772-778.	1.7	20
122	Pulmonary embolism: Epidemiology and registries. <i>Presse Medicale</i> , 2015, 44, e377-e383.	1.9	20
123	Predictors of active cancer thromboembolic outcomes. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1192-1198.	3.4	20
124	Clinical Characteristics and Outcomes of Women Presenting with Venous Thromboembolism during Pregnancy and Postpartum Period: Findings from the RIETE Registry. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1454-1462.	3.4	20
125	Quality assessment of peripheral artery disease clinical guidelines. <i>Journal of Vascular Surgery</i> , 2016, 63, 1091-1098.	1.1	19
126	Infection as cause of immobility and occurrence of venous thromboembolism: analysis of 1635 medical cases from the RIETE registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 404-412.	2.1	19



#	ARTICLE	IF	CITATIONS
127	Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism. <i>Heliyon</i> , 2017, 3, e00229.	3.2	19
128	Raised Fibrinogen Levels and Outcome in Outpatients With Peripheral Artery Disease. <i>Angiology</i> , 2018, 69, 507-512.	1.8	19
129	Severe renal impairment and risk of bleeding during anticoagulation for venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1728-1737.	3.8	18
130	Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry. <i>Viruses</i> , 2022, 14, 178.	3.3	18
131	Platelet count and outcome in patients with acute venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2013, 110, 1025-1034.	3.4	17
132	Clinical characteristics of patients with factor V Leiden or prothrombin G20210A and a first episode of venous thromboembolism. Findings from the RIETE Registry. <i>Thrombosis Research</i> , 2010, 126, 283-286.	1.7	16
133	Renal function and short-term outcome in stable outpatients with coronary, cerebrovascular or peripheral artery disease. <i>Atherosclerosis</i> , 2013, 229, 258-262.	0.8	16
134	Cardiac Rehabilitation and Outcome in Stable Outpatients With Recent Myocardial Infarction. <i>Archives of Physical Medicine and Rehabilitation</i> , 2014, 95, 322-329.	0.9	16
135	D-dimer levels and 90-day outcome in patients with acute pulmonary embolism with or without cancer. <i>Thrombosis Research</i> , 2014, 133, 384-389.	1.7	16
136	Subsequent arterial ischemic events in patients receiving anticoagulant therapy for venous thromboembolism. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2015, 3, 135-141.e1.	1.6	16
137	Type 2 diabetes is associated with a higher incidence of hospitalization for pulmonary embolism in Spain: Analysis of hospital discharge data during 2004-2013. <i>Respirology</i> , 2016, 21, 1277-1284.	2.3	16
138	Inferior vena cava agenesis in patients with lower limb deep vein thrombosis in the RIETE registry. When and why to suspect. <i>International Journal of Cardiology</i> , 2020, 305, 115-119.	1.7	16
139	Validation of a prognostic score for hidden cancer in unprovoked venous thromboembolism. <i>PLoS ONE</i> , 2018, 13, e0194673.	2.5	16
140	Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis. <i>Blood Advances</i> , 2022, 6, 4516-4523.	5.2	16
141	Limited diagnostic workup for deep vein thrombosis after major joint surgery. <i>Thrombosis and Haemostasis</i> , 2008, 99, 1112-1115.	3.4	15
142	Differences in cardiovascular mortality in smokers, past-smokers and non-smokers. <i>European Journal of Internal Medicine</i> , 2009, 20, 522-526.	2.2	15
143	Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism. <i>American Journal of Medicine</i> , 2018, 131, 430-437.	1.5	15
144	Direct Oral Anticoagulants or Standard Anticoagulant Therapy in Fragile Patients with Venous Thromboembolism. <i>TH Open</i> , 2019, 03, e67-e76.	1.4	15

#	ARTICLE	IF	CITATIONS
145	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. <i>JAMA Cardiology</i> , 2022, 7, 747.	6.1	15
146	Clinical Presentation and Short- and Long-term Outcomes in Patients With Isolated Distal Deep Vein Thrombosis vs Proximal Deep Vein Thrombosis in the RIETE Registry. <i>JAMA Cardiology</i> , 2022, 7, 857.	6.1	15
147	Occult Thyrotoxicosis in Patients with Atrial Fibrillation and an Acute Arterial Embolism. <i>Angiology</i> , 1988, 39, 981-985.	1.8	14
148	Unsuspected pulmonary embolism in patients with cancer. <i>Thrombosis Research</i> , 2012, 129, S16-S19.	1.7	14
149	Anemia and Outcome in Outpatients With Peripheral Artery Disease. <i>Angiology</i> , 2016, 67, 484-489.	1.8	14
150	Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism. <i>Chest</i> , 2022, 161, 524-534.	0.8	14
151	Effect of the time of diagnosis on outcome in patients with acute venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2011, 105, 45-51.	3.4	13
152	Clinical outcome in patients with venous thromboembolism receiving concomitant anticoagulant and antiplatelet therapy. <i>European Journal of Internal Medicine</i> , 2014, 25, 821-825.	2.2	13
153	Cilostazol and outcome in outpatients with peripheral artery disease. <i>Thrombosis Research</i> , 2014, 134, 331-335.	1.7	13
154	Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 429-438.	3.8	13
155	Rate and duration of hospitalisation for acute pulmonary embolism in the real-world clinical practice of different countries: analysis from the RIETE registry. <i>European Respiratory Journal</i> , 2019, 53, 1801677.	6.7	13
156	Systolic blood pressure and mortality in acute symptomatic pulmonary embolism. <i>International Journal of Cardiology</i> , 2020, 302, 157-163.	1.7	13
157	Recurrence of venous thromboembolism in patients with recent gestational deep vein thrombosis or pulmonary embolism: Findings from the RIETE Registry. <i>European Journal of Internal Medicine</i> , 2016, 32, 53-59.	2.2	12
158	Uterine bleeding during anticoagulation in women with venous thromboembolism. <i>Thrombosis Research</i> , 2017, 151, S1-S5.	1.7	12
159	Impact of Thrombus Sidedness on Presentation and Outcomes of Patients with Proximal Lower Extremity Deep Vein Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 341-347.	2.7	12
160	Statin and all-cause mortality in patients receiving anticoagulant therapy for venous thromboembolism. Data from the RIETE registry. <i>European Journal of Internal Medicine</i> , 2019, 68, 30-35.	2.2	12
161	Management and outcomes of cancer patients with venous thromboembolism presenting with thrombocytopenia. <i>Thrombosis Research</i> , 2020, 195, 139-145.	1.7	12
162	Comparative clinical prognosis of massive and non-massive pulmonary embolism: A registry-based cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 408-416.	3.8	12

#	ARTICLE	IF	CITATIONS
163	Consenso multidisciplinar para el manejo de la tromboembolia de pulmÃ³n. Archivos De Bronconeumologia, 2022, 58, 246-254.	0.8	12
164	Prolonged travel and venous thromboembolism findings from the RIETE registry. Thrombosis Research, 2010, 126, 287-291.	1.7	11
165	Pulmonary embolism, acute coronary syndrome and ischemic stroke in the Spanish National Discharge Database. European Journal of Internal Medicine, 2016, 28, 65-69.	2.2	11
166	FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence. Clinical and Translational Oncology, 2017, 19, 997-1009.	2.4	11
167	Management and outcome of major bleeding in patients receiving vitamin K antagonists for venous thromboembolism. Thrombosis Research, 2018, 171, 74-80.	1.7	11
168	Management of venous thromboembolism in patients with cancer. Journal of Thrombosis and Haemostasis, 2018, 16, 2391-2396.	3.8	11
169	Randomised controlled trial of a prognostic assessment and management pathway to reduce the length of hospital stay in normotensive patients with acute pulmonary embolism. European Respiratory Journal, 2022, 59, 2100412.	6.7	11
170	Pulmonary embolism in patients over 90 years of age. Current Opinion in Pulmonary Medicine, 2010, 16, 432-436.	2.6	10
171	Thrombophilia and venous thromboembolism: RIETE experience. Best Practice and Research in Clinical Haematology, 2012, 25, 285-294.	1.7	10
172	Predictors of outcome in stable outpatients with peripheral artery disease. Internal and Emergency Medicine, 2014, 9, 69-77.	2.0	10
173	The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry. Thrombosis Research, 2017, 157, 181-188.	1.7	10
174	Systematic review of efficacy and safety of retrievable inferior vena caval filters. Thrombosis Research, 2018, 165, 79-82.	1.7	10
175	Thirty-day outcomes in patients with acute pulmonary embolism who discontinued anticoagulant therapy before 90 days. American Heart Journal, 2018, 206, 1-10.	2.7	10
176	Venous thromboembolism in young adults: Findings from the RIETE registry. European Journal of Internal Medicine, 2019, 63, 27-33.	2.2	10
177	Incidence of major adverse cardiovascular events among patients with provoked and unprovoked venous thromboembolism: Findings from the Registro Informatizado de Enfermedad TromboembÃ³lica Registry. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2020, 8, 353-359.e1.	1.6	10
178	Outcomes after Vena Cava Filter Use in Patients with Cancer-Associated Venous Thromboembolism and Contraindications to Anticoagulation. Thrombosis and Haemostasis, 2020, 120, 1035-1044.	3.4	10
179	Morbid Obesity and Mortality in Patients With VTE. Chest, 2020, 157, 1617-1625.	0.8	10
180	Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 168-178.	2.3	10

#	ARTICLE	IF	CITATIONS
181	Validation of a Prognostic Score to Identify Hospitalized Patients with COVID-19 at Increased Risk for Bleeding. <i>Viruses</i> , 2021, 13, 2278.	3.3	10
182	A Prognostic Score to Identify Low-risk Outpatients with Acute Deep Vein Thrombosis in the Lower Limbs. <i>American Journal of Medicine</i> , 2015, 128, 90.e9-90.e15.	1.5	9
183	Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation. <i>American Journal of Medicine</i> , 2017, 130, 482.e1-482.e9.	1.5	9
184	Mortality after pulmonary embolism in patients with diabetes. Findings from the RIETE registry. <i>European Journal of Internal Medicine</i> , 2019, 59, 46-52.	2.2	9
185	The rationale, design, and methods of a randomized, controlled trial to evaluate the efficacy and safety of an active strategy for the diagnosis and treatment of acute pulmonary embolism during exacerbations of chronic obstructive pulmonary disease. <i>Clinical Cardiology</i> , 2019, 42, 346-351.	1.8	9
186	Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism. <i>Internal and Emergency Medicine</i> , 2019, 14, 1101-1112.	2.0	9
187	Comparison of quality of life measurements: EQ-5D-5L versus disease/treatment-specific measures in pulmonary embolism and deep vein thrombosis. <i>Quality of Life Research</i> , 2019, 28, 1155-1177.	3.1	9
188	Association of Inferior Vena Cava Filter Use With Mortality Rates in Older Adults With Acute Pulmonary Embolism. <i>JAMA Internal Medicine</i> , 2019, 179, 263.	5.1	9
189	Rivaroxaban or apixaban in fragile patients with acute venous thromboembolism. <i>Thrombosis Research</i> , 2020, 193, 160-165.	1.7	9
190	Clinical characteristics and 3-month outcomes in cancer patients with incidental <i>versus</i> clinically suspected and confirmed pulmonary embolism. <i>European Respiratory Journal</i> , 2021, 58, 2002723.	6.7	9
191	Screening for occult cancer in patients with acute venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 2389-2390.	3.8	8
192	Bleeding and venous thromboembolism arising in acutely ill hospitalized medical patients. Findings from the Spanish National Discharge Database. <i>European Journal of Internal Medicine</i> , 2014, 25, 137-141.	2.2	8
193	A prognostic score to identify low-risk outpatients with acute deep vein thrombosis in the upper extremity. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1274-1278.	3.8	8
194	Platelet Count and Major Bleeding in Patients Receiving Vitamin K Antagonists for Acute Venous Thromboembolism, Findings From Real World Clinical Practice. <i>Medicine (United States)</i> , 2015, 94, e1915.	1.0	8
195	Venous thromboembolism in centenarians: Findings from the RIETE registry. <i>European Journal of Internal Medicine</i> , 2016, 36, 62-66.	2.2	8
196	Supervised versus non-supervised exercise in patients with recent myocardial infarction: A propensity analysis. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 245-252.	1.8	8
197	Fatal pulmonary embolism or bleeding in patients with venous thromboembolism: implications of real-life data. <i>Thrombosis Research</i> , 2019, 181, S6-S9.	1.7	8
198	Patient-Level, Institutional, and Temporal Variations in Use of Imaging Modalities to Confirm Pulmonary Embolism. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, e010651.	2.6	8

#	ARTICLE	IF	CITATIONS
199	Thirty-day outcomes in patients with proximal deep vein thrombosis who discontinued anticoagulant therapy prematurely. <i>Thrombosis Research</i> , 2020, 189, 61-68.	1.7	8
200	The effect of COPD on the incidence and mortality of hospitalized patients with pulmonary embolism: A nationwide population-based study (2016-2018). <i>European Journal of Internal Medicine</i> , 2021, 84, 18-23.	2.2	8
201	Systematic testing for venous thromboembolism in hospitalized patients with COVID-19 and raised D-dimer levels. <i>Thrombosis Update</i> , 2021, 2, 100029.	0.9	8
202	Outcome of Cancer-Associated Venous Thromboembolism Is More Favorable among Patients with Hematologic Malignancies than in Those with Solid Tumors. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1594-1602.	3.4	8
203	Influence of recent immobilization or surgery on mortality in cancer patients with venous thromboembolism. <i>Thrombosis Research</i> , 2014, 133, S29-S34.	1.7	7
204	Gender differences in patients with venous thromboembolism and five common sites of cancer. <i>Thrombosis Research</i> , 2017, 151, S16-S20.	1.7	7
205	Role of a clinical prediction score in a chronic thromboembolic pulmonary hypertension rule-out strategy. <i>European Respiratory Journal</i> , 2018, 51, 1702576.	6.7	7
206	Clinical Characteristics and Outcomes of Patients with Lung Cancer and Venous Thromboembolism. <i>TH Open</i> , 2018, 02, e210-e217.	1.4	7
207	Comparison of All-Cause Mortality Following VTE Treatment Between Propensity Score-Adjusted Observational Studies and Matched Randomized Controlled Trials. <i>Chest</i> , 2019, 155, 689-698.	0.8	7
208	Changing Trends in Hospital Admissions for Pulmonary Embolism in Spain from 2001 to 2018. <i>Journal of Clinical Medicine</i> , 2020, 9, 3221.	2.4	7
209	Timing and characteristics of venous thromboembolism after noncancer surgery. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2021, 9, 859-867.e2.	1.6	7
210	Comparing low-molecular-weight heparin dosing for treatment of venous thromboembolism in patients with obesity (RIETE registry). <i>Blood Advances</i> , 2020, 4, 2460-2467.	5.2	7
211	Recovery from acute kidney injury in patients with pulmonary embolism: A single-center study. <i>Thrombosis Research</i> , 2021, 199, 106-109.	1.7	7
212	Management of unsuspected pulmonary embolism in cancer patients. <i>Expert Review of Hematology</i> , 2013, 6, 83-89.	2.2	6
213	Venous thromboembolism in patients with glioblastoma multiforme: Findings of the RIETE registry. <i>Thrombosis Research</i> , 2015, 136, 1199-1203.	1.7	6
214	Sex Differences in Patients With Occult Cancer After Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 489-495.	1.7	6
215	Venous Thromboembolism in Patients With Autoimmune Disorders: Findings From the RIETE Registry. <i>Angiology</i> , 2020, 71, 131-138.	1.8	6
216	Proton pump inhibitors and risk for recurrent ischemic events or death in outpatients with symptomatic artery disease. <i>Atherosclerosis</i> , 2020, 292, 84-89.	0.8	6

#	ARTICLE	IF	CITATIONS
217	Different Types of Statins and All-Cause Mortality during Anticoagulation for Venous Thromboembolism: Validation Study from RIETE Registry. TH Open, 2020, 04, e236-e244.	1.4	6
218	Risk of recurrent venous thromboembolism in patients with autoimmune diseases: data from the Registro Informatizado de Enfermedad TromboEmbólica (RIETE) registry. British Journal of Haematology, 2021, 194, 195-199.	2.5	6
219	Outcomes in patients with acute pulmonary embolism and patent foramen ovale: Findings from the RIETE registry. Thrombosis Research, 2021, 202, 59-66.	1.7	6
220	Systolic Blood Pressure and Outcomes in Stable Outpatients with Recent Symptomatic Artery Disease: A Population-Based Longitudinal Study. International Journal of Environmental Research and Public Health, 2021, 18, 9348.	2.6	6
221	Ventilation/perfusion (V/Q) scanning in contemporary patients with pulmonary embolism: utilization rates and predictors of use in a multinational study. Journal of Thrombosis and Thrombolysis, 2022, 53, 829-840.	2.1	6
222	Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12736.	2.3	6
223	The impact of disseminated intravascular coagulation on the outcome of cancer patients with venous thromboembolism. Blood Coagulation and Fibrinolysis, 2015, 26, 709-711.	1.0	5
224	Venous thromboembolism in patients immobilised at home. European Respiratory Journal, 2015, 45, 1728-1731.	6.7	5
225	Prior thromboprophylaxis and outcome in patients experiencing acute venous thromboembolism after an acute medical illness. European Journal of Internal Medicine, 2016, 30, 72-76.	2.2	5
226	Outcome after discontinuing anticoagulant therapy in women with venous thromboembolism during hormonal use. Thrombosis Research, 2017, 151, S6-S10.	1.7	5
227	Predictors of Early Mortality in Cancer-Associated Thrombosis: Analysis of the RIETE Database. TH Open, 2018, 02, e158-e166.	1.4	5
228	Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years. Scientific Reports, 2019, 9, 20064.	3.3	5
229	Venous thromboembolism in solid-organ transplant recipients: Findings from the RIETE registry. Thrombosis Research, 2021, 201, 131-138.	1.7	5
230	Prediction of Major Bleeding in Anticoagulated Patients for Venous Thromboembolism: Comparison of the RIETE and the VTE-BLEED Scores. TH Open, 2021, 05, e319-e328.	1.4	5
231	Major bleeding events in stable outpatients with coronary, cerebrovascular or peripheral artery disease: findings from the FRENA registry. Journal of Thrombosis and Haemostasis, 2009, 7, 1414-1416.	3.8	4
232	Gender-related differences in the outcome of patients with venous thromboembolism and thrombophilia. Thrombosis Research, 2017, 151, S11-S15.	1.7	4
233	Clinical Course of Venous Thromboembolism in Patients with Pancreatic Cancer: Insights from the RIETE Registry. Thrombosis and Haemostasis, 2018, 118, 1119-1122.	3.4	4
234	Initial strides for invent-VTE: Towards global collaboration to accelerate clinical research in venous thromboembolism. Thrombosis Research, 2018, 163, 128-131.	1.7	4

#	ARTICLE	IF	CITATIONS
235	Pulmonary embolism in Europe remains a cause of concern despite declining deaths. <i>Lancet Respiratory Medicine</i> , 2020, 8, 222-224.	10.7	4
236	Management of isolated distal deep vein thrombosis with direct oral anticoagulants in the RIETE registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 532-541.	2.1	4
237	Outcomes after venous thromboembolism in patients with gastric cancer: Analysis of the RIETE Registry. <i>Vascular Medicine</i> , 2020, 25, 210-217.	1.5	4
238	Predicting the risk for major bleeding in elderly patients with venous thromboembolism using the Charlson index. Findings from the RIETE. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 1017-1025.	2.1	4
239	RIETE Registry: Past, Present and Future. <i>Archivos De Bronconeumologia</i> , 2022, 58, 205-207.	0.8	4
240	Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism. <i>Journal of the American Heart Association</i> , 2021, 10, e021467.	3.7	4
241	PICO Questions and DELPHI Methodology for the Management of Venous Thromboembolism Associated with COVID-19. <i>Viruses</i> , 2021, 13, 2128.	3.3	4
242	A RIETE registry analysis of patients with upper extremity deep vein thrombosis and thoracic outlet syndrome. <i>Thrombosis Research</i> , 2022, 213, 65-70.	1.7	4
243	Clinical characteristics, time course, and outcomes of major bleeding according to bleeding site in patients with venous thromboembolism. <i>Thrombosis Research</i> , 2022, 211, 10-18.	1.7	4
244	[Translated article] Multidisciplinary consensus for the management of pulmonary thromboembolism. <i>Archivos De Bronconeumologia</i> , 2022, 58, T246-T254.	0.8	4
245	How well do European patients understand cancer-associated thrombosis? A patient survey. <i>Cancer Treatment and Research Communications</i> , 2022, 31, 100557.	1.7	4
246	Statin use and 30-day mortality in patients with acute symptomatic pulmonary embolism. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1839-1851.	3.8	4
247	Outcomes beyond the Third Month of Anticoagulation in Patients Aged >75 Years with a First Episode of Unprovoked Venous Thromboembolism. <i>TH Open</i> , 2018, 02, e428-e436.	1.4	3
248	Psychotropic Drugs and Outcome in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism. <i>Thrombosis and Haemostasis</i> , 2020, 120, 620-626.	3.4	3
249	Outcome of patients with acute symptomatic pulmonary embolism and psychiatric disorders. <i>Thrombosis Research</i> , 2020, 193, 90-97.	1.7	3
250	Evaluation of the SAME-TT2R2 score to predict the quality of anticoagulation control in patients with venous thromboembolism treated with vitamin K antagonists: Findings from the RIETE registry. <i>Thrombosis Research</i> , 2020, 194, 178-182.	1.7	3
251	&lt;p&gt;Platelet Count and Bleeding in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism: Lesson from the RIETE Registry&lt;/p&gt;. <i>Journal of Blood Medicine</i> , 2019, Volume 10, 453-456.	1.7	3
252	Prognostic Significance of Concomitant Superficial Vein Thrombosis in Patients with Deep Vein Thrombosis of the Lower Limbs. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1650-1659.	3.4	3

#	ARTICLE	IF	CITATIONS
253	Prognostic impact of acute kidney injury in patients with acute pulmonary embolism data from the RIETE registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 58-66.	2.1	3
254	Women's representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment. <i>Contemporary Clinical Trials</i> , 2022, 115, 106714.	1.8	3
255	Sustained low-density lipoprotein cholesterol <70 mg/dl is associated with improved cardiovascular outcomes in the clinical setting. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13732.	3.4	3
256	Sex Differences in Presentation, Risk Factors, Drug and Interventional Therapies, and Outcomes of Elderly Patients with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study. <i>Thrombosis Research</i> , 2022, 214, 122-131.	1.7	3
257	Recent trends in use of inferior vena caval filters in US older adults with acute pulmonary embolism. <i>Thrombosis Research</i> , 2020, 186, 78-79.	1.7	2
258	Imaging modalities for confirming pulmonary embolism during pregnancy: results from a multicenter international study. <i>European Radiology</i> , 2022, 32, 1238-1246.	4.5	2
259	Sex-differences in the effect of obstructive sleep apnea on patients hospitalized with pulmonary embolism and on in-hospital mortality. <i>Scientific Reports</i> , 2021, 11, 18390.	3.3	2
260	Natural history of patients developing thrombocytopenia while receiving anticoagulant therapy for venous thromboembolism. <i>International Angiology</i> , 2012, 31, 92-5.	0.9	2
261	The impact of advanced age on anticoagulant therapy for acute venous thromboembolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 27-37.	3.3	2
262	Gastroduodenal ulcer incidence in patients with venous thromboembolism. <i>Gastrointestinal Endoscopy</i> , 1989, 35, 386-388.	1.0	1
263	Anticoagulant use in cancer patients. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 351-362.	1.8	1
264	Los registros de pacientes y la investigación clínica. <i>Revista Clinica Espanola</i> , 2017, 217, 23-24.	0.6	1
265	Response. <i>Chest</i> , 2017, 151, 728-729.	0.8	1
266	Real-Time Dissemination of Aggregate Data on Presentation and Outcomes of Patients With Venous Thromboembolism: The RIETE Infographics Project. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962093120.	1.7	1
267	Risk for post-thrombotic syndrome after lower-limb deep vein thrombosis: location of the thrombus or residual thrombi?. <i>Angiologia I Sosudistaia Khirurgiia = Angiology and Vascular Surgery</i> , 2021, 27, 62.	0.1	1
268	Refinement of a modified simplified Pulmonary Embolism Severity Index for elderly patients with acute pulmonary embolism. <i>International Journal of Cardiology</i> , 2021, 335, 111-117.	1.7	1
269	Comparison of Full-Dose vs Moderate-Dose Systemic Thrombolysis for the Treatment of Patients With Acute Pulmonary Embolism. <i>Chest</i> , 2022, 162, 448-451.	0.8	1
270	Prognostic Impact of Active Cigarette Smoking on Mortality in Patients with Acute Venous Thromboembolic Events, Findings from Real World Data. <i>Medicina (Lithuania)</i> , 2022, 58, 295.	2.0	1



#	ARTICLE	IF	CITATIONS
271	The Reply. American Journal of Medicine, 2017, 130, e271.	1.5	0
272	Edoxaban for the Long-Term Therapy of Venous Thromboembolism: Should the Criteria for Dose Reduction be Revised?. Clinical and Translational Science, 2021, 14, 335-342.	3.1	0